HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $14.22, but opened at $15.07. HUTCHMED shares last traded at $15.15, with a volume of 56,261 shares.
Analysts Set New Price Targets
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
Check Out Our Latest Stock Report on HUTCHMED
HUTCHMED Trading Down 2.2 %
The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50 day simple moving average of $14.76 and a 200-day simple moving average of $16.42.
Institutional Investors Weigh In On HUTCHMED
A number of large investors have recently bought and sold shares of HCM. Jane Street Group LLC grew its stake in shares of HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after buying an additional 49,366 shares during the period. XY Capital Ltd acquired a new stake in HUTCHMED in the fourth quarter valued at approximately $673,000. ABC Arbitrage SA bought a new stake in shares of HUTCHMED during the fourth quarter valued at approximately $500,000. Renaissance Technologies LLC raised its position in shares of HUTCHMED by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock worth $2,717,000 after purchasing an additional 29,239 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in shares of HUTCHMED in the 3rd quarter worth $421,000. 8.82% of the stock is currently owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
